BiotechTube
Home/Numab Innovation/Barbara Angehrn
BA

Barbara Angehrn

Chief Executive Officer

Numab Innovation

Therapeutic Areas

ImmunologyOncologyOphthalmology

Numab Innovation Pipeline

DrugIndicationPhase
NM26Atopic DermatitisPre-clinical
NM81Inflammatory Bowel Disease (IBD)Pre-clinical
Boehringer Ingelheim Program 1Retinal DiseasesPre-clinical
Boehringer Ingelheim Program 2Oncology (T-cell engager)Pre-clinical

Leadership Team at Numab Innovation

MG
Mireia Gómez-Angelats
Chief Business Officer
TG
Tea Gunde
VP Scientific Evaluation
View full Numab Innovation profile